(Full list at NCBI or Google Scholar or Researchgate or ORCID)
► Cetin M, Saatci O, Rezaeian A-H, Rao C. N, Beneker C, Sreenivas K, Taylor H, Pederson B, Chatzistamou I, Buckley B, Lessner S, Angel P, McInnes C, Sahin O*(2024). A highly potent bi-thiazole inhibitor of LOX rewires collagen architecture and enhances chemoresponse in triple-negative breast cancer. Cell Chem. Biology 2024; 31:1-16.
► Saatci O, Alam R, Huynh-Dam KT, Isik A, Uner M, Belder , Ersan PG, Tokat UM, Ulukan B, Cetin M, Calisir K, Gedik ME, Bal H, Sener Sahin O, Riazalhosseini D, Thieffry D, Gautheret D, Ogretmen B, Aksoy S, Uner A, Akyol A & Sahin O*. Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer. Cell Death Dis 15, 418 (2024). doi.org/10.1038/s41419-024-06814-3
► Gedik ME, Saatci O, Oberholtzer N, Uner M, Akbulut-Caliskan O, Cetin M, Aras M, Ibis K, Caliskan B, Banoglu E, Wiemann S, Uner A, Aksoy S, Mehrotra S, Sahin O* (2024). Targeting TACC3 induces immunogenic cell death and enhances T-DM1 response in HER2-positive breast cancer. Cancer Research. doi.org/10.1158/0008-5472.CAN-23-2812
► Saatci O, Cetin M, Uner M, Unal M, Chatzistamou I, Ersan P, Montaudon E, Akyol A, Aksoy S, Uner A, Marangoni E, Sajish M, Sahin O* (2023). Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer. Nature Communications. doi: 10.1038/s41467-023-42736-y
► Saatci O, Akbulut O, Cetin M, Sikirzhytski V, Uner M, Lengerli D, O’Quinn E, Romeo M, Caliskan B, Banoglu E, Aksoy S, Uner A and Sahin O* (2023). Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification. Cell Death & Differentiation. doi: 10.1038/s41418-023-01140-1
► Cicek E, Circir A, Oyken M, Akbulut Caliskan O, Dioken DN, Guntekin Ergun S, Cetin-Atalay R, Sapmaz A, Ovaa H, Sahin O, Erson-Bensan AE (2022). EGF-SNX3-EGFR axis drives tumor progression and metastasis in triple-negative breast cancers. Oncogene. 41(2):220-32. doi: 10.1038/s41388-021-02086-9
► Wang L, Londono LM, Cowell J, Saatci O, Aras M, Ersan PG, Serra S, Pei H, Clift R, Zhao Q, Phan KB, Huang L, LaBarre MJ, Li X, Shepard HM, Deaglio S, Linden J, Thanos CD, Sahin O, Cekic C (2021). Targeting Adenosine with Adenosine Deaminase 2 to Inhibit Growth of Solid Tumors. Cancer Research. 81(12):3319-32. doi: 10.1158/0008-5472.CAN-21-0340
► Saatci O, Kaymak A, Raza U, Ersan PG, Akbulut O, Banister CE, Sikirzhytski V, Tokat UM, Aykut G, Ansari SA, Dogan HT, Dogan M, Jandaghi P, Isik A, Gundogdu F, Kosemehmetoglu K, Dizdar O, Aksoy S, Akyol A, Uner A, Buckhaults PJ, Riazalhosseini Y, Sahin O* (2020). Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer. Nature Communications. 11(1):2416. doi: 10.1038/s41467-020-16199-4
► Akbulut O, Lengerli D, Saatci O, Duman E, Seker UO, Isik A, Akyol A, Caliskan B, Banoglu E, Sahin O* (2020). A Highly Potent TACC3 Inhibitor as a Novel Anti-cancer Drug Candidate. Molecular Cancer Therapeutics. 19(6):1243–54. doi: 10.1158/1535-7163.MCT-19-0957
► Siddiqui A, Gollavilli PN, Schwab A, Vazakidou ME, Ersan PG, Ramakrishnan M, Pluim D, Coggins SA, Saatci O, Annaratone L, Schellens JHM, Kim B, Asangani IA, Rasheed SAK, Marchiò C, Sahin O, Ceppi P (2019). Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers. Cell Death & Differentiation. 26(11):2223-36. doi: 10.1038/s41418-019-0289-6
► Saatci Ö, Borgoni S, Akbulut Ö, Durmuş S, Raza U, Eyüpoğlu E, Alkan C, Akyol A, Kütük Ö, Wiemann S, Sahin O* (2018). Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer. Oncogene. 37(17):2251-69. doi: 10.1038/s41388-017-0108-9
► Mishra RR, Belder N, Ansari SA, Kayhan M, Bal H, Raza U, Ersan PG, Tokat ÜM, Eyüpoğlu E, Saatci Ö, Jandaghi P, Wiemann S, Üner A, Cekic C, Riazalhosseini Y, Sahin O* (2018). Reactivation of cAMP pathway by PDE4D inhibition represents a novel druggable axis for overcoming tamoxifen resistance in ER-positive breast cancer. Clinical Cancer Research. 24(8):1987-2001. doi: 10.1158/1078-0432.CCR-17-2776
► Xu J, Acharya S, Sahin O, Zhang Q, Saito Y, Yao J, Wang H, Li P, Zhang L, Lowery FJ, Kuo WL (2015). 14-3-3ζ turns TGF-β’s function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2. Cancer Cell. 27(2):177-92. doi: 10.1016/j.ccell.2014.11.025
► Sahin O, Wang Q, Brady SW, Ellis K, Wang H, Chang CC, Zhang Q, Priya P, Zhu R, Wong ST, Landis MD (2014). Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors. Cell Research. 24(5):542-59. doi: 10.1038/cr.2014.37
► Uhlmann S, Mannsperger H, Zhang JD, Horvat EÁ, Schmidt C, Küblbeck M, Henjes F, Ward A, Tschulena U, Zweig K, Korf U, Wiemann S, Sahin O* (2012). Global microRNA level regulation of EGFR‐driven cell‐cycle protein network in breast cancer. Molecular Systems Biology. 8(1):570-85. doi: 10.1038/msb.2011.100
► Jurmeister S, Baumann M, Balwierz A, Keklikoglou I, Ward A, Uhlmann S, Zhang JD, Wiemann S, Sahin O* (2012). MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F. Molecular and Cellular Biology. 32(3):633-51. doi: 10.1128/MCB.06212-11
► Uhlmann S, Zhang JD, Schwäger A, Mannsperger H, Riazalhosseini Y, Burmester S, Ward A, Korf U, Wiemann S, Sahin O* (2010). miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. Oncogene. 29(30):4297-306. doi: 10.1038/onc.2010.201